Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Tao L. Han

China Japan Union Hospital Of Jilin University
Changchun, CN 
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
China Japan Union Hospital Of Jilin University
Changchun, CN 
OverviewLocationsClinical Research

Overview

Tao Han practices in Changchun, China. Han is rated as an Experienced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Liver Failure, Cirrhosis, Hepatitis B, Liver Transplant, and Mastectomy.

Their clinical research consists of co-authoring 507 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

China Japan Union Hospital of Jilin University
Changchun, 130033, China
Other Locations
No. 22 Qixiangtai Road, Tianjin, 300070, China
99 Shangda Road, Baoshan, 200444, China
Zhongshan Road 321, Nanjing, 210008, China
1037 Luoyu Road, Wuhan, 430074, China
Institutes Of Health Central Plains, Xinxiang, 453003, China
155 Nanjing North Street, Shenyang, 110001, China
71 Xinmin Street, Changchun, 130021, China
800 Dongchuan Road, Shanghai, 200240, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Study Phase: Phase 3
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
View 1 Less Clinical Trial

507 Total Publications

YAP ameliorates CCl4-induced acute liver injury by activating autophagy via modulating p300/CBP-mediated FoxO3 acetylation.
YAP ameliorates CCl4-induced acute liver injury by activating autophagy via modulating p300/CBP-mediated FoxO3 acetylation.
Journal: International immunopharmacology
Published: July 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Han's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 84 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile